Aileron Therapeutics, Inc

(NASDAQ:ALRN)

Latest On Aileron Therapeutics, Inc (ALRN):

Date/Time Type Description Signal Details
2023-02-21 21:16 ESTNewsAileron off 38% on plans to explore sale after setback for cancer candidateN/A
2022-11-30 13:09 ESTNewsAileron regains compliance with Nasdaq's minimum bid price requirementN/A
2022-11-01 22:09 ESTNewsAileron Therapeutics GAAP EPS of -$0.07 beats by $0.01N/A
2022-08-16 04:03 ESTNewsAileron Therapeutics GAAP EPS of -$0.09N/A
2022-08-01 21:49 ESTNewsAileron slips 12% after announcing changes to breast cancer trial designN/A
2022-06-29 11:27 ESTNewsAileron drug fails to beat placebo in reducing chemo toxicities in lung cancer patients in trialN/A
2022-05-19 16:37 ESTNewsAileron begins dosing in phase 1b trial of ALRN-6924 to prevent toxicities due to chemotherapyN/A
2022-05-05 20:55 ESTNewsAileron Therapeutics GAAP EPS of -$0.09 misses by $0.01N/A
2022-03-29 21:36 ESTNewsAileron Therapeutics GAAP EPS of -$0.08 in-lineN/A
2022-01-05 16:52 ESTNewsAileron Therapeutics outlines 2022 strategic priorities to deliver key milestonesN/A
2021-10-22 01:45 ESTNewsAileron Therapeutics: An Assessment On A Lottery TicketN/A
2021-09-21 11:32 ESTNewsAileron Therapeutics EPS beats by $0.01N/A
2021-09-17 12:47 ESTNewsAileron Therapeutics presents new ALRN-6924 data at ESMO virtual congress 2021N/A
2021-08-27 23:39 ESTNewsAileron Therapeutics presents initial findings from ALRN-6924 study in healthy volunteersN/A
2021-07-20 18:23 ESTNewsAileron Therapeutics to join Russell Microcap IndexN/A
2021-07-20 18:20 ESTNewsAileron Therapeutics launches ALRN-6924 trial in patients with advanced non-small cell lung cancerN/A
2021-05-01 03:27 ESTNewsAileron Therapeutics: Solving Chemotherapy's ToxicityN/A
2021-03-25 08:56 ESTNewsAileron Therapeutics EPS misses by $0.02N/A
2021-03-12 19:56 ESTNewsAileron Therapeutics (ALRN) Investor Presentation - SlideshowN/A
2021-02-28 19:37 ESTNewsOur First Look At Aileron TherapeuticsN/A
2021-02-10 06:23 ESTNewsAileron Therapeutics: Low Cash Balance, Early Stage, But Scientific Premise Is InterestingN/A
2021-01-13 11:05 ESTAnalyst RatingThe Analyst Target Price has decreased from $5 to $4.Neutral
2021-01-09 04:18 ESTNewsAileron Therapeutics +31% on insider buying more sharesN/A
2021-01-06 16:52 ESTNewsAileron raises $40M via equity offeringN/A
2020-12-13 03:09 ESTFinancialsCompany financials have been released.Neutral
2020-12-11 15:07 ESTFinancialsCompany financials have been released.Neutral
2020-11-25 11:13 ESTFinancialsCompany financials have been released.Neutral
2020-11-16 07:06 ESTFinancialsCompany financials have been released.Neutral
2020-11-13 20:38 ESTNewsAileron Therapeutics EPS in-lineN/A
2020-11-13 03:09 ESTEarnings EstimateAn EPS average of -$0.09 is estimated for the quarter ending on March 31, 2021.Buy
2020-11-01 16:58 ESTFinancialsCompany financials have been released.Neutral
2020-10-26 10:37 ESTNewsAileron Therapeutics reports positive proof-of-concept data from early-stage ALRN-6924 study in lung cancerN/A
2020-10-17 14:32 ESTNewsStocks To Watch: GM's Hummer Charges The EV Party, Earnings BlitzN/A
2020-10-13 01:51 ESTNewsAileron to announce PoC data from early-stage study with chemoprotection agentN/A
2020-09-26 04:09 ESTFinancialsCompany financials have been released.Neutral
2020-09-22 21:49 ESTNewsAileron Therapeutics inks $15M stock purchase deal with Lincoln Park CapitalN/A
2020-08-07 08:05 ESTFinancialsCompany financials have been released.Neutral
2020-08-07 08:05 ESTAnalyst RatingThe Analyst Target Price has increased from $4 to $5.Buy
2020-08-06 09:46 ESTNewsAileron rallies on advancement of lead drug in early-stage studyN/A
2020-08-04 06:33 ESTNewsAileron concludes enrollment in dose optimization expansion cohort in early stage study of chemotherapeutic agentN/A
2020-07-31 00:07 ESTFinancialsCompany financials have been released.Neutral
2020-07-28 15:46 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 16:11 ESTFinancialsCompany financials have been released.Neutral
2020-07-22 14:06 ESTNewsAileron Therapeutics enrolls first patient in schedule optimization part of early-stage study for ALRN-6924N/A
2020-06-17 17:01 ESTInsider TradeReinhard J. Ambros has directly acquired 5,800 shares and currently holds 5,800 shares.Buy
2020-06-09 21:17 ESTInsider TradeMuneer A Satter has indirectly acquired of 3,700,000 shares.Buy
2020-06-09 21:16 ESTInsider TradeRICKENBACH JOSEF H VON has directly acquired 227,272 shares and currently holds 445,460 shares.Buy
2020-06-08 08:04 ESTAnalyst RatingThe Analyst Target Price has decreased from $4.33 to $4.Neutral
2020-06-05 01:07 ESTNewsAileron Therapeutics -17% on pricing of public offering at $1.10N/A
2020-06-03 20:37 ESTNewsAileron readies equity offeringN/A

About Aileron Therapeutics, Inc (ALRN):

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of stabilized cell-permeating alpha-helical peptides in the oncology and other therapeutic areas in the United States. The company's lead product candidate is ALRN-6924, a cell-permeating peptide, which is in Phase 2a clinical trial for the treatment of advanced solid tumors; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS. It also develops next generation wild type p53 reactivator. Aileron Therapeutics, Inc. has a collaboration agreement with Dana-Farber/Boston Children's Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924; and Pfizer to evaluate the combination of ALRN-6924 and IBRANCE in MDM2-amplified cancers. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is headquartered in Watertown, Massachusetts.

ALRN Quotes by TradingView

See Advanced Chart

General

  • Name Aileron Therapeutics, Inc
  • Symbol ALRN
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 13
  • Fiscal Year EndDecember
  • IPO Date2017-06-29
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.aileronrx.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 11.48
  • Enterprise Value EBITDA 0.05
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.12
  • Return on Assets -53%
  • Return on Equity -133%
  • Earnings Per Share -$1.61
  • Revenue Per Share $0
  • Gross Profit -17663000
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 137.12 million
  • EBITDA -27878000
  • Analyst Target Price $4
  • Book Value Per Share $0.31
View More

Share Statistics

  • Shares Outstanding 83.61 million
  • Shares Float 36.21 million
  • % Held by Insiders 3156%
  • % Held by Institutions 14.43%
  • Shares Short 1.13 million
  • Shares Short Prior Month 1.23 million
  • Short Ratio 0.29
  • Short % of Float 1%
  • Short % of Shares Outstanding 1%
View More

Technicals

  • Beta 2.9
  • 52 Week High $2.47
  • 52 Week Low $0.3
  • 50 Day Moving Average 1.75
  • 200 Day Moving Average 1.43
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Aileron Therapeutics, Inc (ALRN) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Aileron Therapeutics, Inc (ALRN) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-12$N/A-$0.13-$0.145.45%
2020-06-302020-08-05$N/A-$0.14-$0.1925.01%
2020-03-312020-05-11$N/A-$0.24-$0.21-14.29%
2019-12-312020-03-30$N/A-$0.26-$0.274.59%
2019-09-302019-11-07$N/A-$0.28-$0.24-17.89%
2019-06-302019-08-06$N/A-$0.26-$0.22-16.85%
2019-03-312019-05-08$N/A-$0.49-$0.39-26.45%
2018-12-312019-03-29$N/A-$0.48-$0.528.27%
2018-09-302018-11-07$N/A-$0.50-$0.569.91%
2018-06-302018-08-07$N/A-$0.64-$0.52-23.08%
2018-03-312018-05-09$N/A-$0.52-$0.50-4%
2017-09-302017-11-09$N/A-$0.45-$0.35-30.43%
2017-06-302017-08-10$N/A-$0.41-$0.41-0.88%

Aileron Therapeutics, Inc (ALRN) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Research Development N/A N/A 4.07 million N/A N/A
Income Before Tax N/A N/A -6.75 million N/A N/A
Selling General Administrative N/A N/A 2.81 million N/A N/A
Gross Profit N/A N/A N/A N/A N/A
Ebit N/A N/A -6.81 million N/A N/A
Operating Income N/A N/A -6.88 million N/A N/A
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A 66000 N/A N/A
Net Income From Continuing Operations N/A N/A -6.75 million N/A N/A
Net Income Applicable to Common Shares -5.02 million -4.39 million N/A -7.24 million N/A
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A 11.06 million N/A N/A
Change to Liabilities 10000 -96000 N/A -880000 N/A
Total Cash Flow from Investing Activities -4.53 million 239000 N/A 4.76 million N/A
Net Borrowings N/A 384000 N/A N/A N/A
Total Cash Flow from Financial Activities N/A N/A N/A N/A N/A
Change to Operating Activities -526000 -1.21 million N/A 1.31 million N/A
Change in Cash N/A N/A 5.39 million N/A N/A
Total Cash from Operating Activities -5.04 million -5.07 million -5.67 million -6.31 million N/A
Depreciation N/A N/A 70000 N/A N/A
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income 482000 554000 N/A 423000 N/A
Capital Expenditures N/A N/A N/A N/A N/A
Balance Sheet:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Total Liabailities N/A N/A 10.6 million N/A N/A
Total Stockholder Equity N/A N/A 9.77 million N/A N/A
Other Current Liabilities N/A N/A 281000 N/A N/A
Total Assets N/A N/A 20.37 million N/A N/A
Common Stock 40000 39000 N/A 28000 N/A
Other Current Assets 25000 N/A N/A N/A N/A
Retained Earnings -214.3 million -209.27 million -204.88 million -198.14 million N/A
Other Liabilities N/A N/A N/A N/A N/A
Other Assets 568000 568000 N/A 568000 N/A
Cash N/A N/A 10.7 million N/A N/A
Total Current Liabilities 5.25 million N/A 6.14 million N/A N/A
Other Stockholder Equity -1000 -2000 N/A 7000 N/A
Property, Plant & Equipment 5.7 million 5.89 million N/A 6.36 million N/A
Total Current Assets 15.97 million N/A 13.69 million N/A N/A
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 12.46 million 16.65 million N/A 16.05 million N/A
Short Term Investments N/A N/A 2 million N/A N/A
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 1 million N/A 1.09 million N/A N/A

Aileron Therapeutics, Inc (ALRN) Chart:

Aileron Therapeutics, Inc (ALRN) News:

Below you will find a list of latest news for Aileron Therapeutics, Inc (ALRN) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Aileron Therapeutics, Inc (ALRN) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest ALRN Trades:

Date Shares Price
Jun 13, 2022 7:50 PM EST100$0.3731

Aileron Therapeutics, Inc (ALRN) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924320017544/0000899243-20-017544-index.htm
2018-08-15UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1420565/000000000018025320/0000000000-18-025320-index.htm
2019-05-07UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1420565/000000000019008164/0000000000-19-008164-index.htm
2019-05-23UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1420565/000000000019008871/0000000000-19-008871-index.htm
2020-08-18UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1420565/000000000020007567/0000000000-20-007567-index.htm
2019-04-09SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1420565/000005341719000081/0000053417-19-000081-index.htm
2019-11-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1420565/000005341719000097/0000053417-19-000097-index.htm
2020-02-03SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1420565/000005341720000009/0000053417-20-000009-index.htm
2020-06-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1420565/000089534520000689/0000895345-20-000689-index.htm
2018-09-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924318024025/0000899243-18-024025-index.htm
2018-11-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924318028336/0000899243-18-028336-index.htm
2018-11-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924318028338/0000899243-18-028338-index.htm
2018-11-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924318028339/0000899243-18-028339-index.htm
2019-02-253Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924319004731/0000899243-19-004731-index.htm
2019-02-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924319004732/0000899243-19-004732-index.htm
2019-04-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924319009889/0000899243-19-009889-index.htm
2019-04-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924319009890/0000899243-19-009890-index.htm
2019-04-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924319009893/0000899243-19-009893-index.htm
2019-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924319009894/0000899243-19-009894-index.htm
2019-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924319010811/0000899243-19-010811-index.htm
2019-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924319010812/0000899243-19-010812-index.htm
2019-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924319010813/0000899243-19-010813-index.htm
2019-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924319010815/0000899243-19-010815-index.htm
2019-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924319010818/0000899243-19-010818-index.htm
2019-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924319010819/0000899243-19-010819-index.htm
2019-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924319017788/0000899243-19-017788-index.htm
2019-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924319017791/0000899243-19-017791-index.htm
2019-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924319017792/0000899243-19-017792-index.htm
2019-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924319017793/0000899243-19-017793-index.htm
2019-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924319017794/0000899243-19-017794-index.htm
2019-06-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924319017961/0000899243-19-017961-index.htm
2019-06-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924319017964/0000899243-19-017964-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924319017965/0000899243-19-017965-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924319017968/0000899243-19-017968-index.htm
2019-08-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924319021791/0000899243-19-021791-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924319022104/0000899243-19-022104-index.htm
2019-09-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924319022676/0000899243-19-022676-index.htm
2019-09-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924319022724/0000899243-19-022724-index.htm
2019-09-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924319022827/0000899243-19-022827-index.htm
2019-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924319023645/0000899243-19-023645-index.htm
2019-11-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924319027279/0000899243-19-027279-index.htm
2019-11-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924319027510/0000899243-19-027510-index.htm
2020-02-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924320002802/0000899243-20-002802-index.htm
2020-02-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924320002804/0000899243-20-002804-index.htm
2020-02-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924320002805/0000899243-20-002805-index.htm
2020-02-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924320002807/0000899243-20-002807-index.htm
2020-02-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924320002808/0000899243-20-002808-index.htm
2020-06-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924320015868/0000899243-20-015868-index.htm
2020-06-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924320015869/0000899243-20-015869-index.htm
2020-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924320016859/0000899243-20-016859-index.htm
2020-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924320017079/0000899243-20-017079-index.htm
2020-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924320017080/0000899243-20-017080-index.htm
2020-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924320017083/0000899243-20-017083-index.htm
2020-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924320017084/0000899243-20-017084-index.htm
2020-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924320017085/0000899243-20-017085-index.htm
2020-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924320017086/0000899243-20-017086-index.htm
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000089924320017544/0000899243-20-017544-index.htm
2019-04-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1420565/000091957419002794/0000919574-19-002794-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1420565/000091957420001429/0000919574-20-001429-index.htm
2018-08-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000092542118000292/0000925421-18-000292-index.htm
2018-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000092542118000294/0000925421-18-000294-index.htm
2018-08-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000092542118000300/0000925421-18-000300-index.htm
2019-03-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000092542119000114/0000925421-19-000114-index.htm
2019-04-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1420565/000092542119000143/0000925421-19-000143-index.htm
2018-08-22SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1420565/000110465918053210/0001104659-18-053210-index.htm
2019-03-18SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1420565/000110465919015611/0001104659-19-015611-index.htm
2019-04-03SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1420565/000110465919019491/0001104659-19-019491-index.htm
2020-03-18SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1420565/000110465920034979/0001104659-20-034979-index.htm
2020-04-13SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1420565/000110465920045923/0001104659-20-045923-index.htm
2020-04-16SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1420565/000110465920047182/0001104659-20-047182-index.htm
2019-04-26SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1420565/000113777419000066/0001137774-19-000066-index.htm
2019-11-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1420565/000113777419000101/0001137774-19-000101-index.htm
2019-08-13SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1420565/000114420419039589/0001144204-19-039589-index.htm
2018-08-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1420565/000119312518251712/0001193125-18-251712-index.htm
2018-09-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1420565/000119312518267768/0001193125-18-267768-index.htm
2018-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1420565/000119312518289677/0001193125-18-289677-index.htm
2018-11-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1420565/000119312518328314/0001193125-18-328314-index.htm
2019-03-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1420565/000119312519061077/0001193125-19-061077-index.htm
2019-03-29S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1420565/000119312519091512/0001193125-19-091512-index.htm
2019-04-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1420565/000119312519093267/0001193125-19-093267-index.htm
2019-04-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1420565/000119312519096616/0001193125-19-096616-index.htm
2019-04-10SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1420565/000119312519102918/0001193125-19-102918-index.htm
2019-04-11SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1420565/000119312519103985/0001193125-19-103985-index.htm
2019-04-30DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1420565/000119312519129758/0001193125-19-129758-index.htm
2019-04-30DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1420565/000119312519129788/0001193125-19-129788-index.htm
2019-05-01S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1420565/000119312519130164/0001193125-19-130164-index.htm
2019-05-0810-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1420565/000119312519141185/0001193125-19-141185-index.htm
2019-05-10CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1420565/000119312519144108/0001193125-19-144108-index.htm
2019-05-13S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1420565/000119312519145446/0001193125-19-145446-index.htm
2019-06-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1420565/000119312519166179/0001193125-19-166179-index.htm
2019-06-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1420565/000119312519177496/0001193125-19-177496-index.htm
2019-06-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1420565/000119312519180271/0001193125-19-180271-index.htm
2019-07-01S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1420565/000119312519187446/0001193125-19-187446-index.htm
2019-07-11CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1420565/000119312519192235/0001193125-19-192235-index.htm
2019-07-15POS AMPost-Effective amendments for registration statementhttps://www.sec.gov/Archives/edgar/data/1420565/000119312519194006/0001193125-19-194006-index.htm
2019-07-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1420565/000119312519194040/0001193125-19-194040-index.htm
2019-09-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1420565/000119312519240551/0001193125-19-240551-index.htm
2019-09-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1420565/000119312519258919/0001193125-19-258919-index.htm
2019-12-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1420565/000119312519325557/0001193125-19-325557-index.htm
2020-03-30S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1420565/000119312520091054/0001193125-20-091054-index.htm
2020-04-16PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1420565/000119312520109322/0001193125-20-109322-index.htm
2020-04-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1420565/000119312520114425/0001193125-20-114425-index.htm
2020-04-28DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1420565/000119312520123293/0001193125-20-123293-index.htm
2020-04-28DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1420565/000119312520123300/0001193125-20-123300-index.htm
2020-06-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1420565/000119312520156631/0001193125-20-156631-index.htm
2020-06-03424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1420565/000119312520159482/0001193125-20-159482-index.htm
2020-06-03424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1420565/000119312520159490/0001193125-20-159490-index.htm
2020-06-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1420565/000119312520161540/0001193125-20-161540-index.htm
2020-06-05424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1420565/000119312520162165/0001193125-20-162165-index.htm
2020-06-09SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1420565/000119312520164768/0001193125-20-164768-index.htm
2020-06-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1420565/000119312520166690/0001193125-20-166690-index.htm
2020-06-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1420565/000119312520171927/0001193125-20-171927-index.htm
2020-08-11S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1420565/000119312520216321/0001193125-20-216321-index.htm
2020-08-19CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1420565/000119312520224217/0001193125-20-224217-index.htm
2020-09-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1420565/000119312520244673/0001193125-20-244673-index.htm
2020-09-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1420565/000119312520250624/0001193125-20-250624-index.htm
2020-09-25424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1420565/000119312520254600/0001193125-20-254600-index.htm
2020-10-05S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1420565/000119312520263968/0001193125-20-263968-index.htm
2020-10-15424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1420565/000119312520270369/0001193125-20-270369-index.htm
2020-10-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1420565/000119312520276090/0001193125-20-276090-index.htm
2020-02-14SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1420565/000138713120001830/0001387131-20-001830-index.htm
2018-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1420565/000156459018027987/0001564590-18-027987-index.htm
2019-03-2910-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1420565/000156459019010007/0001564590-19-010007-index.htm
2019-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1420565/000156459019017291/0001564590-19-017291-index.htm
2019-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1420565/000156459019029328/0001564590-19-029328-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1420565/000156459019041324/0001564590-19-041324-index.htm
2020-03-3010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1420565/000156459020014155/0001564590-20-014155-index.htm
2020-05-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1420565/000156459020023862/0001564590-20-023862-index.htm
2020-08-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1420565/000156459020036769/0001564590-20-036769-index.htm
2019-05-14EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1420565/999999999519001121/9999999995-19-001121-index.htm
2019-07-15EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1420565/999999999519001591/9999999995-19-001591-index.htm
2019-07-16EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1420565/999999999519001610/9999999995-19-001610-index.htm
2020-08-21EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1420565/999999999520002222/9999999995-20-002222-index.htm
2020-10-15EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1420565/999999999520002868/9999999995-20-002868-index.htm
2020-06-12CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1420565/999999999720003617/9999999997-20-003617-index.htm

Aileron Therapeutics, Inc (ALRN) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Aileron Therapeutics, Inc (ALRN). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 3156%
Institutional Ownership: 1443%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-09-04RICKENBACH JOSEF H VONDirectorBuy23,225.000.7116,582.65105,043.00https://www.sec.gov/Archives/edgar/data/1420565/000089924319022827/0000899243-19-022827-index.htm
2019-09-12RICKENBACH JOSEF H VONDirectorBuy88,145.000.9886,249.88193,188.00https://www.sec.gov/Archives/edgar/data/1420565/000089924319023645/0000899243-19-023645-index.htm
2019-11-12Jeffrey Allen BaileyDirectorBuy19,894.000.5310,543.8219,894.00https://www.sec.gov/Archives/edgar/data/1420565/000089924319027279/0000899243-19-027279-index.htm
2019-04-01Bioventures Ltd Novartis10% Share HolderSell20,610.001.9039,159.002,079,394.00https://www.sec.gov/Archives/edgar/data/1420565/000092542119000143/0000925421-19-000143-index.htm
2019-03-29Bioventures Ltd Novartis10% Share HolderSell106,540.001.85197,099.002,100,004.00https://www.sec.gov/Archives/edgar/data/1420565/000092542119000143/0000925421-19-000143-index.htm
2019-09-13RICKENBACH JOSEF H VONDirectorBuy25,000.000.9724,255.00218,188.00https://www.sec.gov/Archives/edgar/data/1420565/000089924319023645/0000899243-19-023645-index.htm
2019-03-15Bioventures Ltd Novartis10% Share HolderSell43,800.001.9284,096.002,206,544.00https://www.sec.gov/Archives/edgar/data/1420565/000092542119000114/0000925421-19-000114-index.htm
2019-03-14Bioventures Ltd Novartis10% Share HolderSell13,800.001.8825,944.002,250,344.00https://www.sec.gov/Archives/edgar/data/1420565/000092542119000114/0000925421-19-000114-index.htm
2019-03-13Bioventures Ltd Novartis10% Share HolderSell132,738.002.12281,404.562,264,144.00https://www.sec.gov/Archives/edgar/data/1420565/000092542119000114/0000925421-19-000114-index.htm
2018-08-20Bioventures Ltd Novartis10% Share HolderSell20,388.002.3046,892.402,396,882.00https://www.sec.gov/Archives/edgar/data/1420565/000092542118000300/0000925421-18-000300-index.htm
2018-08-17Bioventures Ltd Novartis10% Share HolderSell8,700.002.1018,270.002,417,270.00https://www.sec.gov/Archives/edgar/data/1420565/000092542118000294/0000925421-18-000294-index.htm
2018-08-16Bioventures Ltd Novartis10% Share HolderSell8,808.002.1018,496.802,425,970.00https://www.sec.gov/Archives/edgar/data/1420565/000092542118000294/0000925421-18-000294-index.htm
2018-08-15Bioventures Ltd Novartis10% Share HolderSell2,635.002.155,665.252,434,778.00https://www.sec.gov/Archives/edgar/data/1420565/000092542118000292/0000925421-18-000292-index.htm
2018-08-14Bioventures Ltd Novartis10% Share HolderSell3,300.002.267,458.002,437,413.00https://www.sec.gov/Archives/edgar/data/1420565/000092542118000292/0000925421-18-000292-index.htm
2019-11-14Jeffrey Allen BaileyDirectorBuy15,858.000.518,087.5835,752.00https://www.sec.gov/Archives/edgar/data/1420565/000089924319027510/0000899243-19-027510-index.htm
2020-06-08RICKENBACH JOSEF H VONDirectorBuy227,272.001.10249,999.20445,460.00https://www.sec.gov/Archives/edgar/data/1420565/000089924320015869/0000899243-20-015869-index.htm
2019-08-13Kathryn GregorySVP, Chief Business OfficerBuy45,000.000.6529,025.0045,000.00https://www.sec.gov/Archives/edgar/data/1420565/000089924319021791/0000899243-19-021791-index.htm
2019-08-29RICKENBACH JOSEF H VONDirectorBuy3,600.000.772,770.9253,352.00https://www.sec.gov/Archives/edgar/data/1420565/000089924319022676/0000899243-19-022676-index.htm
2020-06-15Reinhard J. AmbrosDirectorBuy5,800.001.227,076.005,800.00https://www.sec.gov/Archives/edgar/data/1420565/000089924320016859/0000899243-20-016859-index.htm
2019-08-30RICKENBACH JOSEF H VONDirectorBuy15,000.000.7310,968.0068,352.00https://www.sec.gov/Archives/edgar/data/1420565/000089924319022724/0000899243-19-022724-index.htm
2019-11-15Jeffrey Allen BaileyDirectorBuy39,142.000.5119,962.4274,894.00https://www.sec.gov/Archives/edgar/data/1420565/000089924319027510/0000899243-19-027510-index.htm
2019-08-16Vojo VukovicSVP, Chief Medical OfficerBuy75,000.000.5944,452.5075,000.00https://www.sec.gov/Archives/edgar/data/1420565/000089924319022104/0000899243-19-022104-index.htm
2020-06-08Muneer A SatterDirectorBuy3,700,000.001.104,070,000.007,609,449.00https://www.sec.gov/Archives/edgar/data/1420565/000089924320015868/0000899243-20-015868-index.htm
2019-09-03RICKENBACH JOSEF H VONDirectorBuy13,466.000.709,427.5581,818.00https://www.sec.gov/Archives/edgar/data/1420565/000089924319022724/0000899243-19-022724-index.htm